KMT2A and acute myeloid leukemia: There were however differences in the overall responses to the treatment since mice injected with the aggressive MLL-ALL primary cells exhibited a gradual increase in circulating leukemia cells once the treatment was stopped, an event that was not observed in mice injected with primary AML.